FAN
IBRX icon

Financial Advisors Network’s ImmunityBio IBRX Stock Holding History

Financial Advisors Network’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,000
Closed -$76.7K – 216
2026
Q1 		$76.7K Sell
10,000
-44,050
-81% -$302K 0.01% 202
2025
Q4 		$107K Buy
54,050
+4,050
+8% +$9.18K 0.01% 194
2025
Q3 		$123K Buy
50,000
+20,000
+67% +$51.5K 0.02% 194
2025
Q2 		$79.2K Buy
+30,000
New +$80.7K 0.01% 187
2025
Q1 		– Sell
-20,000
Closed -$51.2K – 196
2024
Q4 		$51.2K Buy
+20,000
New +$83.3K 0.01% 186

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Financial Advisors Network's IBRX Position: Q2 2026 in Review

Financial Advisors Network sold out of ImmunityBio (IBRX) in Q2 2026, closing a stake of 10,000 shares — an estimated $76.7K sold.

Financial Advisors Network first reported a position in IBRX in Q4 2024 and held it in 5 quarters. The position peaked at $123K in Q3 2025. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Financial Advisors Network reported no remaining ImmunityBio position as of Q2 2026 after selling out during the quarter.
  • Financial Advisors Network sold 10,000 ImmunityBio shares in Q2 2026, an estimated $76.7K.
  • Financial Advisors Network first reported a position in ImmunityBio in Q4 2024 and held it in 5 quarters.
  • Financial Advisors Network's ImmunityBio position peaked at $123K in Q3 2025.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Financial Advisors Network's 13F filing for Q2 2026, filed 14 Aug 2026.